Key facts
- This page summarizes Lawrence Bruno's Form 4 filing for CORE LABORATORIES N V.
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 21 Feb 2023, 14:12.
Lawrence Bruno - 16 Feb 2023 Form 4 Insider Report for CORE LABORATORIES N V
- Reporting relationship
- Chairman and CEO, Director
- Issuer ticker
- N/A
- Reported as of
- 16 Feb 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Feb 2023, 14:12:37 UTC
- Prior SEC filing
- 04 Jan 2023
- Next SEC filing
- 03 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Tattoli, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Lawrence Bruno filed Form 4 for CORE LABORATORIES N V on 21 Feb 2023.
Change
- Previous filing in this sequence was filed on 04 Jan 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLB
transaction
Derivative
Performance Shares
Award
- Transaction value
- $0
- Shares
- +155,126
- Change %
- Price
- $0.000000
- Shares after
- 155,126
- Date
- 16 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 155,126
- Exercise price
- $0.000000
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This award vests at the end of a three-year performance period that began on January 1, 2023 and ends on December 31, 2025 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 55th percentile of ROIC of the BPG, and 175% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period.
Footnote F2
The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period.